CN109954000A - Donkey milk is in the food and drug for preparing the purposes in food or drug, treating ulcerative colitis - Google Patents
Donkey milk is in the food and drug for preparing the purposes in food or drug, treating ulcerative colitis Download PDFInfo
- Publication number
- CN109954000A CN109954000A CN201711407369.4A CN201711407369A CN109954000A CN 109954000 A CN109954000 A CN 109954000A CN 201711407369 A CN201711407369 A CN 201711407369A CN 109954000 A CN109954000 A CN 109954000A
- Authority
- CN
- China
- Prior art keywords
- group
- donkey milk
- milk
- mouse
- donkey
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
Abstract
The invention proposes donkey milks in the food and drug for preparing the purposes in food or drug, treating ulcerative colitis.The food or drug are suitable for treatment ulcerative colitis.Food containing donkey milk of the invention or drug can effectively treat ulcerative colitis, provide direction for the treatment of ulcerative colitis, while providing theories integration for the exploitation and functional component of functional donkey milk product.
Description
Technical field
The present invention relates to field of food and medicine.In particular it relates to which donkey milk is preparing the use in food or drug
On the way, the food and drug of ulcerative colitis are treated.
Background technique
Donkey is familiar one of the poultry kind of people, and since B.C. 6000, people began to raise and train donkey.China is
The most country of the global donkey amount of raising has 10,000,000 or more, and year milk production is more than 330,000 tons.But since donkey is mostly meat and labour
With, therefore donkey milk is byproduct as donkey industry and existing.In addition, the real application research of donkey milk nutritive value is still rising
Step section, the deep level development as a kind of functional dairy products is not yet carried out completely, so that donkey milk is as supply of commodities market
Share it is seldom, be hardly formed the industrialization production of certain scale.Therefore, donkey milk actual processing amount is considerably less at present, largely
Donkey milk is wasted.So, how donkey milk is utilized, plays its nutritive value, be worth further investigation.
Summary of the invention
The present invention is directed to solve at least one the technical problems existing in the prior art at least to a certain extent.For this purpose,
The invention proposes donkey milks in the food and drug for preparing the purposes in food or drug, treating ulcerative colitis.This hair
The bright food containing donkey milk or drug can effectively treat ulcerative colitis, provide for the treatment of ulcerative colitis
Direction, while theories integration is provided for the exploitation and functional component of functional donkey milk product.
For this purpose, in one aspect of the invention, the invention proposes donkey milks to prepare the purposes in food or drug.Root
According to the embodiment of the present invention, the food or drug are suitable for treatment ulcerative colitis.Inventor creatively has found, donkey milk
Ulcerative colitis can be effectively treated, provides direction for the alleviation of ulcerative colitis, while being functional donkey milk product
Exploitation and functional component extract provide theories integration.
According to an embodiment of the invention, above-mentioned donkey milk prepare the purposes in food or drug can also have it is following attached
Add technical characteristic:
According to an embodiment of the invention, the donkey milk is suitable for losing weight decrease speed and diarrhea, hematochezia degree.By
This, donkey milk can effectively treat ulcerative colitis.
According to an embodiment of the invention, the donkey milk, which is suitable for reducing colon, shortens degree.Donkey milk can be controlled effectively as a result,
Treat ulcerative colitis.
According to an embodiment of the invention, the donkey milk is suitable for reducing the activity of myeloperoxidase.Donkey milk can have as a result,
Effect ground treatment ulcerative colitis.
According to an embodiment of the invention, the donkey milk is suitable for promoting the expression of close connection GAP-associated protein GAP.Donkey milk energy as a result,
Enough effectively treat ulcerative colitis.
According to an embodiment of the invention, the donkey milk is suitable for promoting the expression of occlusion albumen.Donkey milk can be effectively as a result,
Treat ulcerative colitis.
According to an embodiment of the invention, the donkey milk is suitable for reducing colonic tissue degree of injury.Donkey milk can be effective as a result,
Treat ulcerative colitis in ground.
According to an embodiment of the invention, the donkey milk is suitable for inhibiting the expression of pore-forming protein.Donkey milk can be effectively as a result,
Treat ulcerative colitis.
According to an embodiment of the invention, the donkey milk is suitable for inhibiting the expression of TNF-α.Donkey milk can be controlled effectively as a result,
Treat ulcerative colitis.
According to an embodiment of the invention, the donkey milk is suitable for inhibiting the expression of IL-13.Donkey milk can be controlled effectively as a result,
Treat ulcerative colitis.
According to an embodiment of the invention, the donkey milk be suitable for promoting lactobacillus, Lachnospira, Ruminococcus, quasi- Prey irrigate bacterium,
At least one general Salmonella, rod bacillus and clostridium proliferation inhibit escherich's bacillus, Burkholderia, citric acid fungus and purple monad
At least one proliferation.Donkey milk can effectively treat ulcerative colitis as a result,.
In another aspect of this invention, the invention proposes a kind of food for treating ulcerative colitis.According to the present invention
Embodiment, contain donkey milk in the food.Inventor creatively has found that donkey milk can effectively treat ulcerative colitis
Inflammation provides direction for the alleviation of ulcerative colitis, while the exploitation for functional donkey milk food provides theories integration.
In another aspect of this invention, the invention proposes a kind of drugs for treating ulcerative colitis.According to the present invention
Embodiment, contain donkey milk in the drug.Inventor creatively has found that donkey milk can effectively treat ulcerative colitis
Inflammation provides direction for the alleviation of ulcerative colitis, while providing theories integration for the drug development containing donkey milk.
Additional aspect and advantage of the invention will be set forth in part in the description, and will partially become from the following description
Obviously, or practice through the invention is recognized.
Detailed description of the invention
Above-mentioned and/or additional aspect of the invention and advantage will become from the description of the embodiment in conjunction with the following figures
Obviously and it is readily appreciated that, in which:
Fig. 1 shows changes of weight situation after each group mouse modeling according to an embodiment of the invention；
Fig. 2 shows each group colitis mice DAI scoring variation according to an embodiment of the invention；
Fig. 3 shows each group mouse Colon form and length according to an embodiment of the invention；
Fig. 4 shows each group mouse tissue degree of impairment according to an embodiment of the invention, and (A) normally group HE dyeing is cut
Piece 100 ×；(B) physiological saline group HE stained slice 100 ×；(C) cow's milk group HE stained slice 100 ×；(D) donkey milk group HE is dyed
Slice 100 ×；(E) donkey milk lactalbumin group HE stained slice 100 ×；(F) each group mouse tissue Injury score；
Fig. 5 shows each group mouse MPO activity according to an embodiment of the invention；
Fig. 6 shows each group mouse Claudin2 expression quantity according to an embodiment of the invention；
Fig. 7 shows each group mouse TNF-α expression quantity comparison according to an embodiment of the invention；
Fig. 8 shows every daily weight after each group mouse modeling in accordance with another embodiment of the present invention；
Fig. 9 shows each group colitis mice DAI scoring variation in accordance with another embodiment of the present invention；
Figure 10 shows each group mouse Colon form and length in accordance with another embodiment of the present invention；
Figure 11 shows each group mouse tissue degree of impairment in accordance with another embodiment of the present invention, (A) physiological saline group
HE stained slice 100 ×；(B) milky white milk-globule group HE stained slice 100 ×；(C) 5% lysozyme group HE stained slice 100 ×；
(D) 20% lysozyme group HE stained slice 100 ×；(E) 50% lysozyme group HE stained slice 100 ×；(F) normal group；(G) each
Group mouse tissue Injury score；
Figure 12 shows each group mouse MPO activity in accordance with another embodiment of the present invention；
Figure 13 shows that different disposal group mouse intestinal flora alpha diversity according to an embodiment of the invention compares；
Figure 14 shows different disposal group mouse intestinal flora composition PCOA analysis according to an embodiment of the invention；
Figure 15 shows different disposal group mouse intestinal flora composition variance analysis according to an embodiment of the invention；With
And
Figure 16 shows different disposal group mouse intestinal flora composition contrast difference according to an embodiment of the invention.
Specific embodiment
The embodiment of the present invention is described below in detail.The embodiments described below is exemplary, and is only used for explaining this hair
It is bright, and be not considered as limiting the invention.
The invention proposes donkey milks in the food and medicine for preparing the purposes in food or drug, treating ulcerative colitis
Object.It will be described in greater detail respectively below.
Donkey milk is preparing the purposes in food or drug
In one aspect of the invention, the invention proposes donkey milks to prepare the purposes in food or drug.According to this
The embodiment of invention, food or drug are suitable for treatment ulcerative colitis.Inventor creatively has found that donkey milk can be effective
Ulcerative colitis is treated on ground, provides direction for the alleviation of ulcerative colitis, at the same for the exploitation of functionality donkey milk product and
Functional component, which is extracted, provides theories integration.
According to an embodiment of the invention, the donkey milk is suitable for losing weight decrease speed and diarrhea, hematochezia degree.It suffers from
Animal (such as people, mouse) weight of ulcerative colitis can decrease, and with there is diarrhea, hematochezia symptom.In turn, it sends out
Bright people can significantly reduce weight loss speed, alleviating diarrhoea and hematochezia symptom by keeping patient edible or administration donkey milk.
In turn, show that donkey milk can effectively treat ulcerative colitis.
According to an embodiment of the invention, donkey milk, which is suitable for reducing colon, shortens degree.The intestinal tissue of intact animal is intact, intestines
Formed stools in wall consolidation flexible, enteric cavity.However, the animal intestinal wall fragility with ulcerative colitis is easily broken, it can in enteric cavity
See it is shapeless just, visible bloody stool in some animals enteric cavity.In turn, after inventor keeps patient edible or administration donkey milk, discovery
Infected animal intestinal wall is not easily broken, and visible loose stools or molding excrement in enteric cavity, accidental bloody stool, form is close to normal group.In turn, show
Donkey milk can effectively treat ulcerative colitis.
According to an embodiment of the invention, donkey milk is suitable for reducing the activity of myeloperoxidase.In neutrophil leucocyte there are
Myeloperoxidase (MPO), the amount of enzyme contained by each cell be it is certain, MPO has the ability for making hydrogen-peroxide reduction.Cause
This has reacted the number and degree of inflammation of neutrophil leucocyte by measuring MPO content indirectly.Compared to intact animal, ulcer
The activity of myeloperoxidase of property colitis patient is higher.In turn, after inventor keeps patient edible or administration donkey milk, hair
The activity of existing myeloperoxidase significantly reduces, to show that donkey milk can be played by the activity of reduction myeloperoxidase
The effect for treating ulcerative colitis.
According to an embodiment of the invention, donkey milk is suitable for promoting the expression of close connection GAP-associated protein GAP.
According to an embodiment of the invention, donkey milk is suitable for promoting the expression of occlusion albumen.
Occlusion albumen (Occludin) is also known as Occludin or transmembrane protein, includes two extracellular loops and four transmembrane regions
Domain is responsible for the formation and regulation of cytoskeleton, directly participates in the composition of cell tight junction.Close connection GAP-associated protein GAP (ZO-1)
Also known as close connection GAP-associated protein GAP or cytoplasm attachment protein, in the zonuls occludens between a variety of epithelial cells and endothelial cell,
There are multiple binding sites in cytoplasm.Occludin and ZO-1 interacts, and transmembrane protein and cytoskeleton are linked together,
Constitute cell tight junction.In turn, after inventor keeps patient edible or administration donkey milk, discovery occlusion albumen with closely connect
The expression quantity of GAP-associated protein GAP significantly increases.Show that donkey milk can be by promoting occlusion albumen to connect GAP-associated protein GAP with close as a result,
Expression, increase intestinal tight, play treatment ulcerative colitis effect.
According to an embodiment of the invention, donkey milk is suitable for reducing colonic tissue degree of injury.Donkey milk can be controlled effectively as a result,
Treat ulcerative colitis.
According to an embodiment of the invention, donkey milk is suitable for inhibiting the expression of pore-forming protein.Pore-forming protein (Claudin2) can be
Hydrophobic channel is formed between epithelial cell, reduces epithelial electrical resistance.In turn, after inventor keeps patient edible or administration donkey milk, hair
Ready-made porin expression quantity significantly reduces.Show that donkey milk it is penetrating can to reduce enteron aisle by lowering Claudin2 expression as a result,
Property, to reinforce enteron aisle mechanical barrier, enhance enteron aisle resistance, the resistivity of harmful substance is enhanced.And then it plays treatment and bursts
The effect of ulcer colitis.
According to an embodiment of the invention, donkey milk is suitable for inhibiting the expression of TNF-α.TNF-α can reduce Occludin albumen
Expression, cause gut epithelium permeability increase, negative ions and macromolecular non-selectivity infiltration increase.In turn, inventor makes
After patient eats or donkey milk is administered, it is found that the expression quantity of TNF-α significantly reduces, show that donkey milk passes through the table of inhibition TNF-α
It reaches, promotes the expression of Occludin albumen, so that gut epithelium permeability reduces, to reinforce enteron aisle mechanical barrier, make intestines
Resistance enhancing in road enhances the resistivity of harmful substance.And then play the effect for the treatment of ulcerative colitis.
According to an embodiment of the invention, donkey milk is suitable for inhibiting the expression of IL-13.IL-13 can promote Claudin2 albumen
Expression, gut permeability is dramatically increased, especially to cations such as sodium ions.In turn, inventor keep patient edible or
After donkey milk is administered, it is found that the expression quantity of IL-13 significantly reduces, while the expression quantity of Claudin2 albumen is significantly reduced.As a result,
Show donkey milk by inhibiting the expression of IL-13 to cause gut permeability to reduce to inhibit Claudin2 albumen, to reinforce intestines
Road mechanical barrier enhances enteron aisle resistance, enhances the resistivity of harmful substance.And then play treatment ulcerative colitis
Effect.
According to an embodiment of the invention, donkey milk is suitable for that lactobacillus, Lachnospira, Ruminococcus, quasi- Prey is promoted to irrigate bacterium, Pu Shi
At least one bacterium, rod bacillus and clostridium proliferation inhibit escherich's bacillus, Burkholderia, citric acid fungus and purple monad at least
One of proliferation.Inventors have found that donkey milk can significantly adjust intestinal flora, to play the effect for the treatment of ulcerative colitis.
Term " treatment " used in the present invention obtains desired pharmacology and/or physiologic effect for referring to.The effect
Fruit with regard to completely or partially prevention disease or its symptom for can be it is preventative, and/or just partially or completely cure disease and/
Or it can be for ill-effect caused by disease therapeutic." treatment " used herein covers mammal, particularly people
Disease, comprising: (a) prevents disease (such as prevention ulcerative colitis in being easy the individual that illness but not yet make a definite diagnosis is fallen ill
It is scorching) or illness generation；(b) inhibit disease, such as retardance disease development；Or (c) alleviate disease, such as mitigate relevant to disease
Symptom." treatment " used herein, which is covered, gives drug or compound to individual to treat, cure, alleviate, improve, mitigate or press down
Any medication for making the disease of individual, including but not limited to by the drug administration containing donkey milk described herein to individual in need.
Term " administration " used in herein, which refers to, introduces patient by certain suitable mode for the substance of predetermined amount.
Drug of the invention by any common approach to be administered, as long as it can reach expected tissue.The various sides of administration
Formula is expected, including peritonaeum, vein, muscle, and subcutaneously, cortex takes orally, part, nasal cavity and rectum, but the present invention is not
It is limited to these administration modes illustrated.
The administration frequency and dosage of drug of the present invention can be determined by multiple correlative factors, which includes being controlled
The disease type for the treatment of, administration route, patient age, gender, weight and the severity of disease and medicine as active constituent
Species type.According to some embodiments of the present invention, daily dose can be divided into 1 dose, 2 doses or multi-agent of suitable form, when entire
Between in section with 1 time, 2 times or multiple dosing, as long as reaching therapeutically effective amount.
Term " therapeutically effective amount " refers to that compound is enough to significantly improve the amount of certain symptoms relevant to disease or illness,
It also is that given illness and dosage regimen provide the amount of therapeutic effect.For example, reducing, preventing, prolonging in ulcerative colitis
The drug or compound of any symptom of slow, inhibition or retardance disease or illness should be that treatment is effective.Therapeutically effective amount
Drug or compound do not need to cure disease or illness, but will provide treatment for disease or illness, so that the disease or disease of individual
The symptom that the breaking-out of disease was delayed, and prevented or prevented perhaps disease or illness is alleviated or the time limit quilt of disease or illness
Change such as disease or illness become not serious, or accelerate rehabilitation.
The food for treating ulcerative colitis
In another aspect of this invention, the invention proposes a kind of food for treating ulcerative colitis.According to the present invention
Embodiment, contain donkey milk in food.Inventor creatively has found that donkey milk can effectively treat ulcerative colitis, is
The alleviation of ulcerative colitis provides direction, while the exploitation for functional donkey milk food provides theories integration.
It should be noted that both can only contain donkey milk in food of the invention, such as by processing to raw donkey milk
(as sterilized), is made the donkey milk for meeting food safety；Some raising flavor tastes, stability, nutritive value etc. can also be contained
Acceptable component." acceptable component " refers to when eating pharmaceutical formulation to people and general does not generate allergy or phase
Like the molecular entity and composition of unsuitable reaction, such as digestive discomfort, dizziness etc..
Drug
In another aspect of this invention, the invention proposes a kind of drugs for treating ulcerative colitis.According to the present invention
Embodiment, contain donkey milk in drug.Inventor creatively has found that donkey milk can effectively treat ulcerative colitis, is
The alleviation of ulcerative colitis provides direction, while providing theories integration for the drug development containing donkey milk.
Drug of the invention can further include pharmaceutically acceptable excipient, carrier, adjuvant, solvent or they
Combination.Term " pharmaceutically acceptable " refer to it is when being applied pharmaceutical formulation to people and it is general do not generate allergy or
The molecular entity and composition of similar unsuitable reaction, such as digestive discomfort, dizziness etc..Preferably, the term as used herein
" pharmaceutically acceptable " refers to federal regulator or national government are ratified or United States Pharmacopeia or other medicines generally approved
Enumerated in allusion quotation in animal, be more in particular in used in human body.
The solution of the present invention is explained below in conjunction with embodiment.It will be understood to those of skill in the art that following
Embodiment is merely to illustrate the present invention, and should not be taken as limiting the scope of the invention.Particular technique or item are not specified in embodiment
Part, it described technology or conditions or is carried out according to the literature in the art according to product description.Agents useful for same or instrument
Production firm person is not specified in device, and being can be with conventional products that are commercially available.
Embodiment 1
The animal model of Dextran sulfate sodium (DSS) induction BALB/C mice ulcerative colitis is that current research is burst
The comparatively ideal model of ulcer colitis pathogenesis and medication effect.By establishing DSS guidance model in the present embodiment
Study the pathogenesis and medication effect of ulcerative colitis.
50 6 week old male Balb/c mouse are randomly divided into 5 groups, normal group, model group, donkey milk nursing group, cow's milk feeds
Group and donkey milk albumin nursing group are supported, every group 10, sterile water is given and mouse maintains feed.After adaptable fed 5 days, give
Normal group and 0.9% physiological saline of model group intragastric administration on mice are dense to donkey milk group, cow's milk group, the other stomach-filling of donkey milk whey
Contracting donkey milk, concentrated milk now match donkey milk lactoalbumin soln, every stomach-filling 0.3mL, altogether stomach-filling 21 days.After stomach-filling 14 days, normally
Group continues to drink sterile water, and model group, donkey milk nursing group, cow milk feeding group, that donkey milk lactalbumin nursing group drinks 3%DSS is molten
Liquid makes Mouse Ulcerative Colitis Model.During modeling, daily record mouse weight variation, food ration variation, stool and
Hematochezia situation.Modeling 7 days, i.e. stomach-filling is put to death after 21 days, and tissue sample needed for retaining carries out subsequent detection.
1, modeling mouse weight situation of change
As a result as shown in Figure 1.Changes of weight rate indicates mouse weight variation degree, and result of study shows 3%DSS modeling knot
Shu Hou, for modeling group compared with normally group mouse, there is different degrees of reduction in weight, changes obvious (P < 0.05).Wherein exist
In modeling group each group, physiological saline group and cow's milk group weight loss are most violent, and there was no significant difference between the two (P > 0.05) about
6.3% and 6.2%, donkey milk group and the decline of donkey milk albumin group mouse weight are relatively slow, and there was no significant difference (P > 0.05) about
2.4% and 3.3%, weight loss degree significantly reduces (P > 0.05) compared with cow's milk group and physiological saline group.Normal group mouse
Normal-weight fluctuation, it is whole that weight ascendant trend is presented, about rise 3.9%.
2, modeling mouse disease activity index (DAI)
As a result as shown in Fig. 2, after modeling, record mouse weight degree of alleviation, stool and hematochezia situation, and
Disease activity index (DAI) scoring is carried out (according to (the Inhibition of such as Hamamoto to mouse according to standards of grading
dextran sulphate sodium(DSS)-induced colitis in mice by intracolonically
administered antibodies against adhesion molecules(endothelial leucocyte
Adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1))) side
Method scores, then divided by 3, as mouse disease after mouse weight variation, the scoring of stool and hematochezia situation are added
Activity index (DAI)).Normal mouse DAI scoring be 0.50 ± 0.18, modeling group DAI scoring be all remarkably higher than normal mouse (P <
0.05), illustrate modeling success, inflammatory reaction occurs in mouse.It is wherein embodied in, physiological saline group and the scoring point of cow's milk group
Not Wei 3.33 ± 0.50 and 3.05 ± 0.49, the two does not have significant difference (P > 0.05).Donkey milk group DAI scoring for 1.57 ±
0.57, donkey milk lactalbumin group DAI scoring are 1.93 ± 0.36, and the two does not have significant difference (P > 0.05), and significant low
In physiological saline group and cow's milk group, illustrate that oral donkey milk and donkey milk lactalbumin can significantly alleviate the exedens knot of DSS induction
The disease symptoms of enteritis.
3, modeling mouse Colon length changes
As shown in figure 3, putting to death mouse after modeling, and each group mouse Colon form and length are photographed to record after taking colon
Degree.Normal group mouse Colon length is 9.93 ± 0.38cm, and intestinal tissue is intact, excrement in intestinal wall consolidation flexible, enteric cavity
Forming；There was no significant difference (P > 0.05) with cow's milk group colon lengths for physiological saline group in modeling group, respectively 6.17 ±
0.83cm and 6.34 ± 0.79cm, substantially less than normal group mouse (P < 0.05), and intestinal wall fragility is easily broken, in enteric cavity it is visible not at
Shape just, visible bloody stool in some animals enteric cavity；There was no significant difference for donkey milk group and donkey milk lactalbumin group mouse Colon length, point
Not Wei 7.63 ± 0.68cm and 7.19 ± 0.64cm, substantially less than normal group mouse, but be significantly higher than physiological saline group and cow's milk
Group (P < 0.05), and intestinal wall is not easily broken, visible loose stools or molding excrement in enteric cavity, accidental bloody stool, form is close to normal group.
4, mouse Colon tissue damage situation
As a result as shown in Figure 4.After the completion of modeling, mouse is put to death, takes mouse Colon intestinal segment tissue that slice is made and carries out HE dye
Color is observed under the microscope, and carries out histopathological scores.It was found that: normal group mouse Colon crypts is clear in structure, complete,
Marshalling is close, has no ulcer disperse situation, and histopathological scores are 1.14 ± 0.41, substantially less than modeling group each group
(P<0.05).In modeling group, physiological saline group and cow's milk group tissue damage are obvious, and extent of disease is greater than 80%, some animals knot
Intestines extent of disease reaches 100%, and whole crypts are impaired, lose original shape, festers in disperse shape, injured depth reaches entire mucous membrane
Layer, partially involves submucosa, histopathological scores are respectively 11.57 ± 0.51 and 11.00 ± 1.67；Donkey milk lactalbumin
Group mouse Colon tissue damage is lighter than physiological saline group and cow's milk group, and crypts can recognize original shape reluctantly, and tissue damage is commented
It is divided into 4.86 ± 1.26；Donkey milk group tissue damage is most light, and close to normal group mouse tissue form, crypts can still keep original shape
Shape, score of tissue damage are 3.86 ± 0.82, substantially less than physiological saline group and cow's milk group (P < 0.05).
5, myeloperoxidase (MPO) activity
As a result as shown in Figure 5.The normal group mouse Colon tissue MPO minimum 0.85 ± 0.12U/g of activity, substantially less than makes
Mould group each group；Physiological saline group and cow's milk group activity of myeloperoxidase are respectively 2.76 ± 0.23U/g and 2.60 in modeling group
± 0.22U/g, there was no significant difference (P > 0.05)；Donkey milk group and donkey milk lactalbumin group activity of myeloperoxidase are respectively
1.38 ± 0.36U/g and 1.62 ± 0.41U/g, there was no significant difference (P > 0.05) for both this, but is significantly higher than normal group, significantly
Lower than physiological saline group and cow's milk group (P < 0.05).There are MPO in neutrophil leucocyte, the amount of enzyme contained by each cell is one
Fixed, MPO has the ability for making hydrogen-peroxide reduction.Therefore, by measurement MPO activity, neutrophil leucocyte is reflected indirectly
Number and degree of inflammation.
6, Claudin2 expression quantity
As a result as shown in Figure 6.After modeling, mouse Colon tissue is taken, detects the expression of Claudin2.It was found that normal group
Mouse Claudin2 expression quantity is 0.65 ± 0.09ng/mg, substantially less than modeling group each group (P < 0.05)；In modeling group each group,
Physiological saline group and the rising of cow's milk group Claudin2 expression quantity are most violent, and respectively 2.56 ± 0.29ng/mg and 2.32 ±
0.16ng/mg, the two do not have significant difference (P > 0.05)；Donkey milk group and donkey milk lactalbumin group Claudin2 expression quantity difference
For 1.31 ± 0.22ng/mg and 1.61 ± 0.22ng/mg, expression quantity is significantly higher than normal group, but substantially less than physiological saline
Group and cow's milk group (P < 0.05).
7, TNF-α expression quantity
Shown in result figure 7.After modeling, mouse Colon tissue is taken, detects the expression of TNF-α, finds normal group mouse
TNF-α expression quantity is 0.18 ± 0.02ng/mg, substantially less than modeling group each group (P < 0.05)；In modeling group each group, physiological saline
Group and the rising of cow's milk group TNF-α expression quantity are most violent, and respectively 0.39 ± 0.03ng/mg and 0.35 ± 0.02ng/mg, the two do not have
There is significant difference (P > 0.05)；Donkey milk group and donkey milk lactalbumin group TNF-α expression quantity be respectively 0.22 ± 0.02ng/mg and
0.24 ± 0.05ng/mg, expression quantity are significantly higher than normal group, but substantially less than physiological saline group and cow's milk group (P < 0.05).
Brief summary:
After DSS induced ulcerative colitis, stomach-filling donkey milk, donkey milk lactalbumin, the mouse of cow's milk and stomach-filling physiological saline
The mouse of group is compared, and has certain alleviation in weight loss degree, wherein donkey milk group is the most significant.In addition, in mouse essence
Also there is a degree of alleviation in terms of refreshing state, diarrhea, hematochezia.This research is scored with disease activity index (DAI) indicates mouse
Disease severity finds that the mouse extent of donkey milk and donkey milk lactalbumin group is significantly lower than physiological saline and cow's milk stomach-filling
Mouse (P < 0.05).After modeling, each group mouse Colon is taken, it is found that donkey milk and donkey milk lactalbumin group mouse Colon shorten
Degree is significantly lower than physiological saline and cow's milk group (P < 0.05).Take its myeloperoxidase (MPO) of mouse Colon tissue detection living
Property, tissue damage and correlative protein expression have been found that the mouse performance of stomach-filling donkey milk and donkey milk lactalbumin better than stomach-filling physiology
The mouse of salt water and cow's milk, and have significant difference (P < 0.05).
Take stomach-filling after two weeks, the mouse Colon tissue before modeling detects pore-forming protein Claudin2 and inflammatory factor
The expression of TNF-α, discovery stomach-filling donkey milk are compared compared with stomach-filling physiological saline with the mouse of cow's milk with the mouse of donkey milk lactalbumin,
Claudin2 and the expression of TNF-α are lowered, and are illustrated the immune of the oral adjustable normal mouse of donkey milk, are increased intestines
Barrier compactness.It is above simultaneously to study it was found that the effect of stomach-filling donkey milk lactalbumin and the effect of stomach-filling donkey milk are without significant
Sex differernce (P > 0.05), so also it shows that, the substance of main function is played in whey egg to alleviation ulcerative colitis in donkey milk
Bai Zhong.
Embodiment 2
Inventors have found that the content difference of lysozyme is larger in the lactalbumin of donkey milk and cow's milk, wherein bacteriolyze in donkey milk
Enzyme content is more.In turn, it is that lysozyme plays the effect for alleviating ulcerative colitis that inventor, which speculates,.In order in clear donkey milk
Whether active constituent is lysozyme, and the method that inventor takes isoelectric precipitation is enriched with the lysozyme in donkey milk, obtains molten
Bacterium enzyme content be 50% protein mixture and detect activity, be configured to later lysozyme content be 0%, 5%, 20% and 50%
Protein solution stomach-filling mouse and induced ulcerative colitis.Concrete outcome is as follows:
1, modeling mouse weight situation of change
As shown in figure 8, changes of weight rate indicates mouse weight variation degree, result of study shows that 3%DSS modeling terminates
Afterwards, different degrees of reduction occurs for modeling group each group mouse weight compared with normal group, and be changed significantly (P < 0.05), wherein filling
The mitigation of two groups of mouse weights of stomach physiological saline and milky white lactoglobulin is most obvious and there was no significant difference (P > 0.05), about declines
11.8% and 11.5%, remaining each group has different degrees of alleviation compared with physiological saline group, and with the increasing of lysozyme content
Add, weight loss degree gradually becomes significant (P < 0.05): 5% lysozyme group about declines 7.4%, and 20% lysozyme group about declines
6.4%, the decline of 50% lysozyme group mouse weight is most slow, and about 5.9%.Normal group mouse weight is integrally presented weight and rises
Gesture about rises 3.9%.
2, modeling mouse disease activity index (DAI)
As shown in figure 9, after modeling, record each group mouse weight degree of alleviation, stool and hematochezia situation, and
Disease activity index (DAI) scoring is carried out to mouse according to standards of grading.Normal mouse DAI scoring is 0.57 ± 0.25, modeling
Group DAI scoring is all remarkably higher than normal mouse (P < 0.05), illustrates modeling success, and inflammatory reaction occurs in mouse.It is wherein specific
It shows as, physiological saline group and the scoring of milky white milk-globule group are respectively 3.57 ± 0.25 and 3.33 ± 0.23, and the two does not have conspicuousness
Difference (P > 0.05)；50% lysozyme group DAI scoring is minimum, is 1.79 ± 0.75, is significantly higher than normal group but is substantially less than and gives birth to
Manage salt water group and milky white milk-globule group (P < 0.05)；20% lysozyme group DAI scoring is lower than 5% lysozyme group (P > 0.05), significantly
Lower than physiological saline group and milky white milk-globule group (P < 0.05), it is higher than 50% lysozyme group.
3, modeling mouse Colon length changes
As shown in Figure 10, mouse is put to death after modeling, and photographs to record each group mouse Colon form and length after taking colon
Degree finds that normal group mouse Colon length is 9.18 ± 0.53cm, is significantly higher than modeling group each group (P < 0.05), and intestinal tissue
Formed stools in intact, intestinal wall consolidation flexible, enteric cavity；Physiological saline group and milky white milk-globule group colon lengths are without aobvious in modeling group
It writes sex differernce (P > 0.05), respectively 5.53 ± 1.13cm and 5.71 ± 1.29cm, substantially less than 20% lysozyme group (7.17 ±
1.25cm) and 50% lysozyme group (7.85 ± 1.09cm) (P < 0.05)；5% lysozyme colon lengths are 6.19 ± 1.19cm,
Lower than 20% lysozyme group, it is higher than physiological saline group and milky white milk-globule group (P>0.05), substantially less than 50% lysozyme group (P<
0.05)。
4, mouse Colon tissue damage situation
As shown in figure 11, after the completion of modeling, mouse is put to death, takes mouse Colon intestinal segment tissue that slice is made and carries out HE dyeing,
Observation discovery under the microscope: normal group mouse Colon crypts is clear in structure, complete, and marshalling is close, has no ulcer disperse
Situation, histopathological scores are 1.25 ± 0.46, substantially less than modeling group each group (P < 0.05).In modeling group, physiology salt
Water group and milky white milk-globule tissue damage are obvious, and extent of disease is greater than 80%, and some animals colonic pathological change range reaches 100%, entirely
Portion's crypts is impaired, involves epicuticle, and crypts loses original shape, festers in disperse shape, injured depth reaches entire mucous layer, part
Involve submucosa, histopathological scores are respectively 11.37 ± 1.30 and 11.64 ± 1.64, are significantly higher than lysozyme each group
(P<0.05)；In bacteriolyze enzymatic treatment group, 5% lysozyme histopathological scores are 7.88 ± 1.25, substantially less than physiological saline
With milky white milk-globule group (P < 0.05), crypts disperse degree is lower than also below this two groups, has complete epicuticle, extent of disease contracting
It is small；20% dissolution and 50% lysozyme group histopathological scores are respectively 4.88 ± 1.73 and 3.63 ± 0.92, this two groups it
Between there was no significant difference (P > 0.05), be significantly higher than remaining each group of modeling group.20% lysozyme group can identify the specific shape of crypts
Shape, colon extent of disease mitigate less than 5% lysozyme group, inflammatory symptom；50% lysozyme group can obviously tell crypts shape
Shape, it is similar to normal group form.
5, myeloperoxidase (MPO) determination of activity
As shown in figure 12, in neutrophil leucocyte there are MPO, the amount of enzyme contained by each cell be it is certain, MPO has
Make the ability of hydrogen-peroxide reduction.Therefore, by measuring MPO content, the number and inflammation of neutrophil leucocyte have been reacted indirectly
Degree.The normal group mouse Colon tissue MPO minimum 0.92 ± 0.16U/g of activity, substantially less than modeling group each group (P < 0.05)；
In modeling group, physiological saline group and milky white milk-globule group activity of myeloperoxidase be respectively 2.87 ± 0.15U/g and 2.79 ±
0.17U/g, the two do not have significant difference (P > 0.05)；20% lysozyme and 50% lysozyme activity of myeloperoxidase difference
For 1.61 ± 0.18U/g and 1.36 ± 0.22U/g, there was no significant difference for the two (P > 0.05), but substantially less than physiological saline group
With milky white milk-globule group (P < 0.05)；5% lysozyme group activity of myeloperoxidase is 2.06 ± 0.28U/g, is significantly higher than 20%
Lysozyme group and 50% lysozyme group, substantially less than physiological saline group and milky white milk-globule group (P < 0.05).
Brief summary:
Balb/c mouse freely drinks 3%DSS, and the three or four day or so, the symptoms such as weight loss, diarrhea, hematochezia, the 7th day
When, symptom is the most serious.Find that modeling group mouse Colon length is significantly shorter than normal group mouse (P < 0.05), and intestinal wall after dissection
It is thinning, in enteric cavity it is visible it is shapeless just, have kermesinus bloody stool in some animals enteric cavity.It is observed under the microscope after HE dyeing visible
Colon interior ulcer, it is in disperse shape that crypts, which destroys, and lamina propria is impaired, a large amount of inflammatory cell infiltrations, is presented apparent anxious
Ulcerative Colitis symptom shows modeling success.
Mouse state is observed during modeling, find mouse its hair of different material stomach-filling at random, lassitude, lazy move,
Weight loss, diarrhea and hematochezia degree are different.It is scored according to disease activity index (DAI) to separate groups of mice illness severity
It is compared analysis, it is found that the disease reaction of the mouse containing lysozyme in stomach-filling substance is generally lower than in stomach-filling substance without molten
The mouse of bacterium enzyme, and the relaxation effect of disease reaction is reinforced with the raising of lysozyme content in system, not lysozyme
There was no significant difference on the remission effect of disease reaction (P > 0.05) for protein solution and physiological saline.After modeling, take each
Group mouse Colon, find in stomach-filling substance its colon of each group mouse containing lysozyme shorten degree significantly lower than physiological saline with
The protein solution (P < 0.05) that lysozyme content is 0.Mouse Colon tissue detection its myeloperoxidase (MPO) activity is taken, point
Analysis mouse Colon tissue damage is simultaneously scored, and is found in a certain range, as lysozyme content is continuously increased in system, system pair
The relaxation effect of colitis in mice gradually increases, and has significant difference (P < 0.05) with each group of not lysozyme.
The present embodiment the result shows that donkey milk lysozyme truly has remission effect to colitis in mice, remission effect with
The increase of lysozyme content and it is gradually significant.In addition, α-lactalbumin and beta lactoglobulin are to ulcerative colitis without obvious slow
Solution effect.
Embodiment 3
In this embodiment, mouse Colon tight junction protein expression quantity, inflammatory factor after lysozyme are taken by detection
The variation of expression quantity, intestinal flora composition etc., probes into the mechanism of action that lysozyme alleviates colitis in mice.Concrete outcome
It is as follows:
1, tight junction protein expression (Occludin, ZO-1, Claudin2)
The results are shown in Table 1.After modeling, mouse Colon tissue is taken, detects Tight junction protein occludin, ZO-
1, Claudin2 etc. expression, it is found that Occludin and ZO-1 expression in normally group mouse is significantly higher than modeling group each group,
Expression of the Claudin2 in normally group mouse is substantially less than modeling group each group (P < 0.05).In modeling group each group, physiology salt
There was no significant difference in the expression of three kinds of tight junction proteins (P > 0.05) for water group and milky white milk-globule group；With bacteriolyze enzymatic treatment group
It compares, it is found that the presence of lysozyme can promote Tight junction protein occludin and the expression of ZO-1, inhibit Claudin2's
Expression, and with the increase of lysozyme content, promotion/inhibitory effect enhancing, wherein 20% lysozyme group and 50% lysozyme
The expression quantity of Occludin and ZO-1 is significantly higher than physiological saline group and milky white milk-globule group in group, and the expression quantity of Claudin2 is significant
Lower than physiological saline group and milky white milk-globule group (P < 0.05).
1 each group tight junction protein of table expression variation (ng/mg)
| Grouping | Occludin | ZO-1 | Claudin2 |
| Normal group | 18.23±1.38c | 9.76±0.94d | 0.68±0.18a |
| Physiological saline group | 8.53±1.40a | 3.51±0.54a | 2.33±0.47d |
| Milky white milk-globule group | 8.86±1.13a | 3.64±1.03a | 2.20±0.57cd |
| 5% lysozyme group | 10.14±1.57a | 5.58±1.00b | 1.63±0.39bc |
| 20% lysozyme group | 13.18±1.26b | 6.66±0.92bc | 1.30±0.30b |
| 50% lysozyme group | 14.44±2.55b | 7.52±1.02c | 1.05±0.32b |
Note: there is significant difference (P < 0.05) between different letter expression groups.
2, inflammatory factor expression (TNF-α, IL-13)
The results are shown in Table 2.After modeling, mouse Colon tissue, the table of the inflammatory factors such as detection TNF-α, IL-13 are taken
Reach, find normal group mouse TNF-α, IL-13 expression quantity be substantially less than physiological saline group and milky white milk-globule group in modeling group (P <
0.05), there was no significant difference (P > 0.05) with 50% lysozyme group；Physiological saline group and milky white milk-globule group are in TNF-α, IL-13
There was no significant difference in the expression of two kinds of factors (P > 0.05)；Table of the lysozyme group each group to two TNF-α, IL-13 factors
Up to having downward effect, and the raising to lysozyme content, downward effect enhances, wherein 20% lysozyme group and 50% lysozyme group
Middle TNF-α, IL-13 expression quantity significantly reduce (P < 0.05) compared with physiological saline group and milky white milk-globule group.
2 each group inflammatory factor expression amount of table changes (ng/mg)
Note: there is significant difference (P < 0.05) between different letter expression groups.
3, different disposal group intestinal flora otherness detects
(1) bacterial diversity is analyzed
As shown in figure 13, its enterobacteriaceae of high throughput sequencing analysis is carried out to the mouse Colon content of different disposal group
Group, ace index show intestinal flora diversity, and numerical value is bigger to illustrate that bacterial diversity degree is higher.It was found that 3%DSS modeling
Group mouse bacterial diversity is substantially less than normal group mouse (P < 0.05)；In three groups of modeling group, stomach-filling physiological saline and stomach-filling
There was no significant difference on bacterial diversity (P > 0.05) and is substantially less than stomach-filling for the mouse for the solution that lysozyme content is 0%
The mouse (P < 0.05) of 50% lysozyme.Illustrate that lysozyme can alleviate flora caused by the ulcerative colitis of DSS induction
Diversity is reduced.
(2) influence that lysozyme forms mouse intestinal flora
As shown in figure 14, the intestines of physiological saline group, 0% lysozyme group, 50% lysozyme group and normal group mouse are compared
Road flora composition, PC1 and PC2 respectively illustrate always make a variation 51.55% and 16.23%.It can be seen from this figure that after modeling,
Modeling group each group mouse intestinal flora composition, there are larger difference, illustrates that DSS inducing mouse is exedens compared with normally group mouse
Colitis can substantially change mouse intestinal flora composition.In addition, 0% lysozyme group and physiological saline group mouse are in enterobacteriaceae group
It is little at upper difference, and 50% lysozyme group mouse intestinal flora composition has large change compared with this is two groups, illustrates lysozyme
Have an impact to mouse intestinal flora composition.
As shown in figure 15, display belongs in level, each Pseudomonas of relative abundance > 1% in different disposal group.Make a concrete analysis of each bacterium
Belong to accounting variation, it is normal that organize bacteroid S24-7 (Bacteroidales_S24-7) in mouse be dominant bacteria, account for about 41.6%, and
More normal group of S24-7 ratio of mouse bacteroid of modeling group each group is remarkably decreased, and Roche bacterium (Roseburia) content is 3.4%, and
Roche bacterial content < 1% in modeling group each group；Escherich's bacillus (Escherichia-Shigella), Burkholderia
(Blautia), citric acid fungus (Citrobacter), purple monad (Parabacteroides) are in normal group and 50% lysozyme
Relative abundance is lower than 1% in group, and escherich's bacillus accounts for 16.1% He respectively in physiological saline and every group of 0% bacteriolyze
16.3%, Burkholderia category account for respectively 11.8% and 10.0%, citric acid fungus account for 2.3% and 1.2% respectively, purple pseudomonas bacillus category
5.9% and 1.5% are accounted for respectively, are significantly higher than normal group and 50% lysozyme group；Quasi- Prey irrigates bacterium (Alloprevotella) and exists
7.2% and 4.4%, rod bacillus (Alistipes) is accounted for respectively in normal group and 50% lysozyme mouse intestinal flora to account for respectively
3.3% and 2.9%, general Salmonella _ UCG-001 (Prevotellaceae_UCG-001) accounts for 4.8% and 2.0%, cud ball respectively
Bacterium _ UCG-014 (Ruminococcaceaae_UCG-014) accounts for 2.9% and 3.6%, clostridium _ vadinBB60 respectively
(Clostridiales_vadinBB60) 3.2% and 2.5% are accounted for respectively, and in physiological saline group and every group of 0% bacteriolyze, this
A little bacterium proportions substantially reduce；In addition, Lachnospira _ NK4A136 (Lachnospiraceae_NK4A136), Ruminococcus _
UCG-014, proportions content in 50% lysozyme group mouse such as lactobacillus risen, wherein Lachnospira _ NK4A136,
Lactobacillus (Lactobacillus) variation is more significant.
(3) influence of the lysozyme to mouse intestinal bacterium relative abundance
As shown in figure 16, high-flux sequence is carried out to the mouse Colon content that different material is fed, detects its flora kind
Class compares and analyzes in flora category level, and clustering tree shows that physiological saline group mouse and 0% lysozyme group mouse exist between group
Intestinal flora composition is upper to be had differences between 50% lysozyme group and normal group mouse, and physiological saline group mouse and 0% bacteriolyze
Enzyme group mouse is upper similar in flora composition, and 50% lysozyme group mouse is upper similar in intestinal flora composition to normal mouse.
Intestinal flora thermal map, which is shown, is, on belonging to level, 20 Pseudomonas before relative abundance in group.Concrete analysis is not
Difference is formed with nursing group mouse intestinal flora, find stomach-filling physiological saline and 0% lysozyme soln of stomach-filling in modeling group and is filled
50% lysozyme soln of stomach is compared with normal group mouse, and the anaerobic bacteria ratio in enteron aisle is reduced, facultative anaerobic bacteria increasing proportion.Tool
Body is shown as compared with normally group, physiological saline and 0% lysozyme group angstrom Xi Shi-Shigella, Burkholderia category and citric acid
Bacillus is significantly more than 50% lysozyme group and normal group；Quasi- Prey irrigates Pseudomonas and general Salmonella _ UCG-001 is substantially less than 50% bacteriolyze
Enzyme group and normal group；In addition, Bacillus acidi lactici and Lachnospira _ NK4A136 are slightly above remaining each group in 50% lysozyme group.
Brief summary:
Experiment takes each group mouse Colon tissue, the expression of the detection intestinal tight connection albumen such as albumen and inflammatory factor, hair
Now with the increase of lysozyme content, the factor expressions amount such as Tight junction protein occludin, ZO-1 rises, tight junction protein
The expression quantity of the factors such as Claudin2, TNF-α, IL-13 declines, and there are dose relationships for variation.Therefore, lysozyme passes through up-regulation
The expression of Occludin and ZO-1 increases intestinal tight, lowers Claudin2 expression, reduces intestinal permeability, reinforced with this
Enteron aisle mechanical barrier enhances enteron aisle resistance, enhances the resistivity of harmful substance.Exempt from addition, lysozyme can also be adjusted
Epidemic disease.Since the expression of inflammatory factor and the expression of tight junction protein are related, it is possible thereby to infer that lysozyme connects intestinal tight
The adjustment effect for connecing albumen may be by adjusting and be immunized to realize.
It compares physiological saline group, 0% lysozyme group, 50% lysozyme group and normally organizes intestinal flora multiplicity in mouse Colon
Property, it is found that bacterial diversity is significantly higher than its excess-three group, physiological saline group and 0% lysozyme group enteron aisle in normal group mouse intestinal
Bacterial diversity is worst, and the two is distinguished without conspicuousness, and is below 50% lysozyme group.Four groups of enterobacteriaceaes are analyzed in subordinate level
The composition of group finds that compared with physiological saline group and 0% lysozyme group, 50% lysozyme group mouse intestinal flora composition is closer
Normal mouse (flora composition is more early closer to intersecting), physiological saline group and 0% lysozyme group mouse flora composition difference are little,
Illustrate that ulcerative colitis will lead to intestinal bacilli illness, and lysozyme can alleviate this flora imbalance.Specific point
Analysis discovery, compared with normal group, anaerobic bacteria in physiological saline group, 0% lysozyme group and 50% lysozyme group mouse intestinal flora
It is reduced, facultative anaerobic bacteria is increased, this phenomenon is showed in physiological saline group and 0% lysozyme group and is especially apparent.Wherein, intend
Bacillus _ S24-7 is dominant bacteria in normal group, is reduced in three groups of modeling group, has article to show bacteroid _ S24-7
It is related to the alleviation of intestinal inflammatory, reduce the generation for showing enteritis.It compares 50% lysozyme group and physiological saline group and 0% is molten
The discovery of bacterium enzyme group, escherich's bacillus, Burkholderia category, citric acid fungus, purple pseudomonas bacillus in physiological saline group and 0% lysozyme group
Belong to etc. more normal group to rise than content, intend Prey irrigate Pseudomonas, rod bacillus, Pu Shi _ UCG-001, Ruminococcus _ UCG-014 etc. compared with
Normal group declines than content, and in 50% lysozyme group, and Ruminococcus _ UCG-014 is risen, remaining and normal group ratio
It is close.In addition to common escherich's bacillus can cause intestines problem, Burkholderia category, citric acid fungus, purple pseudomonas bacillus category also can
Adverse effect is generated to body, having document to show that Burkholderia belongs to is acetogen, generates adverse effect to enteron aisle；Purple unit cell
Bacillus is a kind of pathogen, and a variety of enterogastric diseases such as peritonitis, ecphyaditis, peritoneal abscess can be caused when increasing；Citric acid
Bacterium is conditioned pathogen, can cause the multi-infections such as diarrhea in Abwehrkraft des Koepers difference.And it is obligate anaerobic that quasi- Prey, which irrigates Pseudomonas,
There is document to find that it can anti-oxidant reduction cardiovascular disease；Rod bacillus, which is reported, can slow down intestinal inflammatory, reduce inflammatory bowel
The generation of disease；General Salmonella _ UCG-001 can promote the building of immune system；Ruminococcus _ UCG-014 has anti-oxidant and adjusts
Immune effect, part of kind may be related with antidepression.In addition, compared with remaining each group, 50% lysozyme group mouse
Lactobacillus and Lachnospira _ NK4A163 proportion dramatically increase in intestinal flora, and wherein lactobacillus has significant prebiotic effect
Fruit can inhibit the growth of pathogen, improve intestinal microflora, enhance body's immunity, reduce cholesterol, improve blood lipid
The effects of, be conducive to intestinal health and immunologic balance, it can also promote Lachnospira _ NK4A163 proliferation, Lachnospira _ NK4A163
To produce butyric, butyric acid, by one of the main dead end product of microbial fermentation, is enterocyte weight as enteron aisle dietary fiber
Energy source is wanted, it maintains enteron aisle homeostasis, in all many-sided immune responses and response to oxidative stress as adjusted host, enhancing
Defensive barrier and improvement permeability of colonic mucosa etc. affect the occurrence and development process of ulcerative colitis.Therefore, illustrate molten
Bacterium enzyme can promote beneficial bacterium proliferation, reduce harmful bacteria proliferation, enhance intestinal mucosa defensive barrier, subtract by adjusting intestinal flora
The generation of few ulcerative colitis.
In the description of this specification, reference term " one embodiment ", " some embodiments ", " example ", " specifically show
The description of example " or " some examples " etc. means specific features, structure, material or spy described in conjunction with this embodiment or example
Point is included at least one embodiment or example of the invention.In the present specification, schematic expression of the above terms are not
It must be directed to identical embodiment or example.Moreover, particular features, structures, materials, or characteristics described can be in office
It can be combined in any suitable manner in one or more embodiment or examples.In addition, without conflicting with each other, the skill of this field
Art personnel can tie the feature of different embodiments or examples described in this specification and different embodiments or examples
It closes and combines.
Although the embodiments of the present invention has been shown and described above, it is to be understood that above-described embodiment is example
Property, it is not considered as limiting the invention, those skilled in the art within the scope of the invention can be to above-mentioned
Embodiment is changed, modifies, replacement and variant.
Claims (10)
1. donkey milk is preparing the purposes in food or drug, which is characterized in that the food or drug are suitable for treatment ulcer
Property colitis.
2. purposes according to claim 1, which is characterized in that the donkey milk is suitable for promoting the table of close connection GAP-associated protein GAP
It reaches.
3. purposes according to claim 1, which is characterized in that the donkey milk is suitable for promoting the expression of occlusion albumen.
4. purposes according to claim 1, which is characterized in that the donkey milk is suitable for reducing the activity of myeloperoxidase.
5. purposes according to claim 1, which is characterized in that the donkey milk is suitable for losing weight decrease speed and abdomen
It rushes down, hematochezia degree；
Optionally, the donkey milk is suitable for reducing colonic tissue degree of injury；
Optionally, the donkey milk is suitable for reducing colon shortening degree.
6. purposes according to claim 1, which is characterized in that the donkey milk is suitable for inhibiting the expression of pore-forming protein.
7. purposes according to claim 1, which is characterized in that the donkey milk is suitable for inhibiting the expression of IL-13；
Optionally, the donkey milk is suitable for inhibiting the expression of TNF-α.
8. purposes according to claim 1, which is characterized in that the donkey milk is suitable for promoting lactobacillus, Lachnospira, cud ball
Bacterium, quasi- Prey irrigate at least one bacterium, general Salmonella, rod bacillus and clostridium proliferation, inhibit escherich's bacillus, Burkholderia, lemon
At least one sour bacterium and purple monad proliferation.
9. a kind of food for treating ulcerative colitis, which is characterized in that contain donkey milk.
10. a kind of drug for treating ulcerative colitis, which is characterized in that contain donkey milk.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711407369.4A CN109954000B (en) | 2017-12-22 | 2017-12-22 | Application of donkey milk in preparation of food or medicine, and food and medicine for treating ulcerative colitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711407369.4A CN109954000B (en) | 2017-12-22 | 2017-12-22 | Application of donkey milk in preparation of food or medicine, and food and medicine for treating ulcerative colitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109954000A true CN109954000A (en) | 2019-07-02 |
| CN109954000B CN109954000B (en) | 2021-02-23 |
Family
ID=67019481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711407369.4A Active CN109954000B (en) | 2017-12-22 | 2017-12-22 | Application of donkey milk in preparation of food or medicine, and food and medicine for treating ulcerative colitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109954000B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116334260A (en) * | 2023-03-17 | 2023-06-27 | 黑龙江中医药大学 | Metabolic biomarker for diagnosing infertility of polycystic ovary syndrome and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150057232A1 (en) * | 2012-02-10 | 2015-02-26 | Ovogenics Sa | Anti-Inflammatory Composition for Modulating the Cell Response of Neutrophils and Eosinophils |
| CN104383272A (en) * | 2014-12-11 | 2015-03-04 | 谭清平 | Traditional Chinese medicine preparation used for treating diabetes |
| CN105636648A (en) * | 2013-09-06 | 2016-06-01 | 雪松-西奈医学中心 | Clusters of polynomials for data points |
| CN105724585A (en) * | 2016-02-28 | 2016-07-06 | 张筱康 | Method for preparing lyophilized donkey milk powder by low temperature sterilization |
-
2017
- 2017-12-22 CN CN201711407369.4A patent/CN109954000B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150057232A1 (en) * | 2012-02-10 | 2015-02-26 | Ovogenics Sa | Anti-Inflammatory Composition for Modulating the Cell Response of Neutrophils and Eosinophils |
| CN105636648A (en) * | 2013-09-06 | 2016-06-01 | 雪松-西奈医学中心 | Clusters of polynomials for data points |
| CN104383272A (en) * | 2014-12-11 | 2015-03-04 | 谭清平 | Traditional Chinese medicine preparation used for treating diabetes |
| CN105724585A (en) * | 2016-02-28 | 2016-07-06 | 张筱康 | Method for preparing lyophilized donkey milk powder by low temperature sterilization |
Non-Patent Citations (8)
| Title |
|---|
| C.COSENTINO等: "Short communication: Jenny milk as an inhibitor of late blowing in cheese: A preliminary report", 《JOURNAL OF DAIRY SCIENCE》 * |
| LUN JIANG等: "Donkey milk lysozyme ameliorates dextran sulfate sodium-induced colitis by improving intestinal barrier function and gut microbiota composition", 《JOURNAL OF FUNCTIONAL FOODS》 * |
| MAGGIE LEE等: "Hen Egg Lysozyme Attenuates Inflammation and Modulates Local Gene Expression in a Porcine Model of Dextran Sodium Sulfate (DSS)-Induced Colitis", 《JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY》 * |
| 周光兴等主编: "《人类疾病动物模型复制方法学》", 31 January 2008, 上海科学技术文献出版社 * |
| 张迎娣等: "肠道菌群在肠道稳态和炎症性肠病中的研究进展", 《胃肠病学》 * |
| 田洪源: "重组溶菌酶特性及其对小鼠肠道菌群的影响研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
| 范玉晶等: "TNF-α、IL-13 在溃疡性结肠炎中的表达及临床意义", 《中华结直肠疾病电子杂志》 * |
| 驴业百科: "驴奶的药用价值", 《搜狐》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116334260A (en) * | 2023-03-17 | 2023-06-27 | 黑龙江中医药大学 | Metabolic biomarker for diagnosing infertility of polycystic ovary syndrome and application thereof |
| CN116334260B (en) * | 2023-03-17 | 2023-12-22 | 黑龙江中医药大学 | Metabolic biomarker for diagnosing infertility of polycystic ovary syndrome and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109954000B (en) | 2021-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2774616B1 (en) | Application of roseburia in treating and preventing obesity related diseases | |
| CN103735838A (en) | Healthcare medicinal liquor capable of nourishing and tonifying kidney and preparation method thereof | |
| EP0546870A1 (en) | Nutritive composition for prevention and therapy of infection diseases caused by immunosuppression | |
| CN108714208A (en) | Composition, preparation method, using and relieve stress, improve sleep product | |
| CN103734581B (en) | Yak milk polypeptide nutrient powder being applicable to postoperative crowd's rehabilitation and preparation method thereof | |
| CN103859030B (en) | A kind of milk beverage of suitable women and preparation method thereof | |
| JP2011241209A (en) | Bdnf production accelerator having ganglioside or derivative thereof as active ingredient, and medical product, food and drink and feed containing the bdnf production accelerator | |
| CN109954000A (en) | Donkey milk is in the food and drug for preparing the purposes in food or drug, treating ulcerative colitis | |
| JP2014129323A (en) | Inhibitor of fat accumulation in liver | |
| CN108142951A (en) | Improve nutraceutical of postoperative insulin resistance and its preparation method and application | |
| CN108066712A (en) | A kind of benefiting qi and nourishing blood Chinese medicine composition | |
| TW201817442A (en) | Composition for improving peripheral neuropathy caused by anticancer agents | |
| CN103920140B (en) | A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation | |
| CN110384240A (en) | Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application | |
| Falender et al. | Postoperative nutritional support in oral and maxillofacial surgery | |
| Mareta et al. | Comparison Of Effectiveness Benefits Of Providing Young Papaya Fruit Extract And Breast Care For Normal Postpartum Mother's Breast Milk Production: Systematic Review | |
| KR101908850B1 (en) | Medicinal-Herb Composition Comprising Chinese matrimony vine for Anti-Obesity and the Method of Making the Same | |
| CN110934828A (en) | Asarone oral emulsion and preparation method thereof | |
| CN104740428B (en) | A kind of compound tonifying blood containing red skin of peanut pharmaceutical preparation and its application and detection method | |
| KR100534066B1 (en) | Mushroom lactic acid fermented solution including effective ingredients for decreasing the value of blood sugar, and method for manufacturing the solution | |
| JP2020100591A (en) | Agent for improving muscle quality | |
| CN109287942A (en) | A kind of health care congee and its preparation, instructions of taking for treating anaemia | |
| CN106798826A (en) | Tuber of dwarf lilyturf oligosaccharides is preparing the application in promoting brown fat generation medicine | |
| CN114177163B (en) | Medicine for treating hypertension | |
| KR20170063257A (en) | Functional food formulations comprising vegetable worms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Guo Huiyuan Inventor after: Ren Fazheng Inventor after: Lv Jiayi Inventor after: Luo Jie Inventor after: Li Yuan Inventor before: Ren Fazheng Inventor before: Lv Jiayi Inventor before: Guo Huiyuan Inventor before: Luo Jie Inventor before: Li Yuan |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |